Analgesic Efficacy of Different Nerve Blocks in Postoperative Cesarean Section
Analgesic Efficacy of Erector Spinae Block , Quadratus Lumborum Block, and Intrathecal Morphine for Postoperative Pain Relief After Cesarean Section: A Randomized Study
1 other identifier
interventional
120
1 country
1
Brief Summary
comparing analgesic efficacy of different nerve blocks on post operative cesarean sections.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 10, 2023
CompletedStudy Start
First participant enrolled
October 15, 2023
CompletedFirst Posted
Study publicly available on registry
October 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 5, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 5, 2025
CompletedApril 9, 2025
April 1, 2025
1.5 years
October 10, 2023
April 6, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Duration of analgesia until first analgesic request.
the time interval from immediate postoperative period until NRS reached 4
24 hours .
Study Arms (3)
Intrathcal Morphine Group
ACTIVE COMPARATORIntrathecal morphine administration for post operative pain relief after cesarean section
Quadratus Lumborum nerve block group
ACTIVE COMPARATORQuadratus Lumborum nerve block administration for post operative pain relief after cesarean section
Erector Spinae nerve block group
ACTIVE COMPARATORErector Spinae nerve block administraion for post operative pain relief after cesarean section
Interventions
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
Eligibility Criteria
You may qualify if:
- years old
- more or equal 37 weeks of gestation
- ASA 1,2
- Elective cesarean delivery
You may not qualify if:
- Patient refusal
- inability to cooperate with or understand the study
- local infection.
- bleeding disorder
- known anaphylaxis to any drug used in the trial
- ASA physical status more than 2
- emergency operations
- chronic opioid use (opioid use in the past 3 months)
- Neurologic deficit or disorder
- contraindication to regional anesthesia.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mahmoud Mamdouh Ekram
Asyut, Manfalout, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator.
Study Record Dates
First Submitted
October 10, 2023
First Posted
October 18, 2023
Study Start
October 15, 2023
Primary Completion
April 5, 2025
Study Completion
April 5, 2025
Last Updated
April 9, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share